ABT 378r: a novel inhibitor of HIV-1 protease in hemodyalisis


Medical Advocates for Social Justice
Journal Papers, Abstracts and Commentaries
		Abstract ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis Hassane Izzedine^a, Vincent Launay-Vacher^a, Mayeule Legrand^b, Deborah Lieberherr^a, Eric Caumes^c, and Gilbert Deray^a AIDS, 2001:15:662-665

This paper is the first pharmacokinetics report on the use of lopinavir/ritonavir in a patient with renal failure. The patient was a 53-year-old HIV-infected man with a history of systemic leishmaniasis that had been treated with amphotericin B for 5 years and who developed chronic renal insufficiency. The patient's ARV regimen was stavudine, didanosine, lamivudine, nevirapine, efavirenz, and lopinavir/ritonavir. No clinical or biological adverse events were noted.

The pharmacokinetics study was conducted after the oral administration of a three soft capsule dose of lopinavir/ritonavir between and during dialysis sessions and the data are summarized in Table 1 in the paper. According to the authors, the data suggest that that lopinavir/ritonavir should be administered at normal dosages
in patients with renal insufficiency undergoing hemodialysis, regardless of the hemodialysis schedule.

Departments of ^aNephrology, Pharmacology, and Infectious Diseases, Pitié Salpétriére Hospital,
47 - 83 Boulevard de l'Hôpital, 75013 Paris, France

Abstract by Gordon Nary

KLS Journal Citations KLS New and Noteworthy Home Page